Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06FMO
|
|||
| Former ID |
DIB002391
|
|||
| Drug Name |
ABP 501
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Rheumatoid arthritis [ICD-11: FA20] | Phase 3 | [1] | |
| Plaque psoriasis [ICD-11: EA90.0; ICD-10: L40.0] | Application submitted | [2] | ||
| Company |
Amgen
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800038738) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Case study: biosimilar anti TNFalpha (Adalimumab) analysis of Fc effector functions. BMC Proc. 2013; 7(Suppl 6): P30. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.